dc.contributor.author | Schott, Eckart | |
dc.contributor.author | Agarwal, Kosh | |
dc.contributor.author | Dumas, Emily O. | |
dc.contributor.author | Gaeta, Giovanni B. | |
dc.contributor.author | Lee, Sam | |
dc.contributor.author | Streinu-Cercel, Adrian | |
dc.contributor.author | Andrade, Raul J. | |
dc.contributor.author | Perez, Alma M. | |
dc.contributor.author | George, Jacob | |
dc.contributor.author | Bakulin, Igor G. | |
dc.contributor.author | Marinho, Rui T. | |
dc.contributor.author | Charafeddine, Mariem | |
dc.contributor.author | Liu, Li | |
dc.contributor.author | Pilot-Matias, Tami | |
dc.contributor.author | Howieson, Kevin | |
dc.contributor.author | Co, Melannie | |
dc.contributor.author | Cohen, Daniel E. | |
dc.contributor.author | Zoulim, Fabien | |
dc.contributor.author | Ozaras, Resat | |
dc.date.accessioned | 2021-03-03T07:37:36Z | |
dc.date.available | 2021-03-03T07:37:36Z | |
dc.identifier.citation | Agarwal K., Dumas E. O. , Gaeta G. B. , Lee S., Streinu-Cercel A., Schott E., Andrade R. J. , Perez A. M. , George J., Bakulin I. G. , et al., "Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I", 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 11 - 15 Kasım 2016, cilt.64 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_12ef62be-8bd0-4ef3-a679-271948a6b514 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/18174 | |
dc.language.iso | eng | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Gastroenteroloji-(Hepatoloji) | |
dc.title | Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I | |
dc.type | Bildiri | |
dc.contributor.department | King''s College Hospital NHS Foundation Trust , , | |
dc.identifier.volume | 64 | |
dc.contributor.firstauthorID | 150372 | |